FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226334833> ?p ?o ?g. }

• W4226334833 endingPage "450" @default.
• W4226334833 startingPage "445" @default.
• W4226334833 abstract "Apalutamide, an androgen receptor signaling inhibitor, in combination with androgen-deprivation therapy (ADT), is approved for treatment of patients with nonmetastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer, based on the data from the phase 3 SPARTAN and TITAN studies respectively. Apalutamide is an inducer of cytochrome P450 enzymes and P-glycoprotein, which are involved in the metabolism of oral anticoagulants (OACs) and may thus have potential drug-drug interactions when co-administered with OACs. Concomitant use of certain OACs such as apixaban, rivaroxaban, edoxaban, dabigatran, and warfarin was allowed in the SPARTAN and TITAN studies. A post-hoc analysis was conducted to evaluate the incidence of treatment-emergent thrombotic and embolic adverse events (AEs) in patients receiving concomitant OACs with apalutamide + ADT or placebo + ADT in both the studies. Anticoagulants were identified by WHO Drug Anatomical Therapeutic Chemical level 4 classifications. Thrombotic and embolic AEs were coded using the Medical Dictionary for Regulatory Activities Version 22.1. Data were analyzed from patients receiving concurrent OACs among all treated patients in SPARTAN (apalutamide + ADT: 95/803 [11.8%]; placebo + ADT: 48/398 [12.1%]) and TITAN (apalutamide + ADT: 31/524 [5.9%]; placebo + ADT: 28/527 [5.3%]). No consequential differences were observed in the occurrence of thrombotic and embolic events between apalutamide + ADT and placebo + ADT groups receiving concomitant OACs in SPARTAN (11.6% vs 12.5%) or TITAN (19.4% vs 21.4%). Grade 3/4 thrombotic and embolic AEs observed in patients receiving concomitant OACs with apalutamide + ADT or placebo + ADT were 6 (6.3%) vs 5 (10.4%) in SPARTAN and 3 (9.7%) vs 1 (3.6%) in TITAN. This analysis suggests that when necessary, concomitant OACs can be used with apalutamide with appropriate monitoring." @default.
• W4226334833 created "2022-05-05" @default.
• W4226334833 creator A5016024490 @default.
• W4226334833 creator A5016944058 @default.
• W4226334833 creator A5024278705 @default.
• W4226334833 creator A5024685539 @default.
• W4226334833 creator A5027536929 @default.
• W4226334833 creator A5032276489 @default.
• W4226334833 creator A5046899948 @default.
• W4226334833 creator A5051153455 @default.
• W4226334833 creator A5066061366 @default.
• W4226334833 creator A5071220712 @default.
• W4226334833 creator A5078572631 @default.
• W4226334833 date "2022-01-01" @default.
• W4226334833 modified "2023-09-28" @default.
• W4226334833 title "Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studies." @default.
• W4226334833 cites W2036946450 @default.
• W4226334833 cites W2055771484 @default.
• W4226334833 cites W2115201106 @default.
• W4226334833 cites W2520740086 @default.
• W4226334833 cites W2792086148 @default.
• W4226334833 cites W2917593000 @default.
• W4226334833 cites W2923408498 @default.
• W4226334833 cites W2946652117 @default.
• W4226334833 cites W2947014957 @default.
• W4226334833 cites W2969591704 @default.
• W4226334833 cites W3083310601 @default.
• W4226334833 cites W3158318954 @default.
• W4226334833 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35141028" @default.
• W4226334833 hasPublicationYear "2022" @default.
• W4226334833 type Work @default.
• W4226334833 citedByCount "1" @default.
• W4226334833 countsByYear W42263348332023 @default.
• W4226334833 crossrefType "journal-article" @default.
• W4226334833 hasAuthorship W4226334833A5016024490 @default.
• W4226334833 hasAuthorship W4226334833A5016944058 @default.
• W4226334833 hasAuthorship W4226334833A5024278705 @default.
• W4226334833 hasAuthorship W4226334833A5024685539 @default.
• W4226334833 hasAuthorship W4226334833A5027536929 @default.
• W4226334833 hasAuthorship W4226334833A5032276489 @default.
• W4226334833 hasAuthorship W4226334833A5046899948 @default.
• W4226334833 hasAuthorship W4226334833A5051153455 @default.
• W4226334833 hasAuthorship W4226334833A5066061366 @default.
• W4226334833 hasAuthorship W4226334833A5071220712 @default.
• W4226334833 hasAuthorship W4226334833A5078572631 @default.
• W4226334833 hasConcept C121608353 @default.
• W4226334833 hasConcept C126322002 @default.
• W4226334833 hasConcept C142724271 @default.
• W4226334833 hasConcept C143998085 @default.
• W4226334833 hasConcept C204787440 @default.
• W4226334833 hasConcept C27081682 @default.
• W4226334833 hasConcept C2779384505 @default.
• W4226334833 hasConcept C2780192828 @default.
• W4226334833 hasConcept C71924100 @default.
• W4226334833 hasConcept C98274493 @default.
• W4226334833 hasConceptScore W4226334833C121608353 @default.
• W4226334833 hasConceptScore W4226334833C126322002 @default.
• W4226334833 hasConceptScore W4226334833C142724271 @default.
• W4226334833 hasConceptScore W4226334833C143998085 @default.
• W4226334833 hasConceptScore W4226334833C204787440 @default.
• W4226334833 hasConceptScore W4226334833C27081682 @default.
• W4226334833 hasConceptScore W4226334833C2779384505 @default.
• W4226334833 hasConceptScore W4226334833C2780192828 @default.
• W4226334833 hasConceptScore W4226334833C71924100 @default.
• W4226334833 hasConceptScore W4226334833C98274493 @default.
• W4226334833 hasIssue "1" @default.
• W4226334833 hasLocation W42263348331 @default.
• W4226334833 hasOpenAccess W4226334833 @default.
• W4226334833 hasPrimaryLocation W42263348331 @default.
• W4226334833 hasRelatedWork W1051628 @default.
• W4226334833 hasRelatedWork W14784210 @default.
• W4226334833 hasRelatedWork W15075455 @default.
• W4226334833 hasRelatedWork W16736519 @default.
• W4226334833 hasRelatedWork W16747189 @default.
• W4226334833 hasRelatedWork W17055214 @default.
• W4226334833 hasRelatedWork W1760914 @default.
• W4226334833 hasRelatedWork W5417165 @default.
• W4226334833 hasRelatedWork W5918682 @default.
• W4226334833 hasRelatedWork W9462154 @default.
• W4226334833 hasVolume "12" @default.
• W4226334833 isParatext "false" @default.
• W4226334833 isRetracted "false" @default.
• W4226334833 workType "article" @default.